Clinical Study

A Phase 2 Randomized Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer

Posted Date: Oct 8, 2014

  • Investigator: Nooshin Hashemi Sadraei
  • Co-Investigator: Null Null
  • Specialties: Hematology/Oncology, Oncology, Cancer, Head & Neck Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone.


To Be Eligible For This Study, Patients Must Have Anaplastic Thyroid Cancer Which Cannot Be Removed With Surgery Or Has Spread To Other Areas Of The Body.


Advanced Anaplastic Thyroid Cancer, Thyroid Cancer, A091305, Cancer, Head & Neck, 2014-5243

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.